Influenza vaccination in patients with end-stage renal disease

Nicola Principi, Susanna Esposito

Research output: Contribution to journalArticle

Abstract

Introduction: Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than desired.Areas covered: This paper explores why compliance with official recommendations for influenza vaccination is poor in patients with ESRD and analyzes the true risk of infection as well as the immunogenicity, the effectiveness and the safety of influenza vaccination in these patients.Expert opinion: Epidemiological and clinical data support the importance of influenza in conditioning clinical deterioration of patients with ESRD, particularly in relation to their level of immunosuppression. However, the variable levels of immunodeficiency detected in patients with ESRD may reduce the immune response to influenza vaccination, which appears to be lower than that usually found in healthy subjects. However, few studies are available, and they are difficult to compare for several reasons. Additionally, limited data have been collected on influenza vaccine effectiveness, although the available studies support positive results of vaccination on outcomes of severe disease. Despite such limitations, it is important to highlight that all the available studies have confirmed the good safety and tolerability of inactivated influenza vaccines. These findings, together with the risks associated with influenza in these patients, support annual influenza vaccination in patients with ESRD as well as vaccination of their close contacts and should be presented in educational programs organized for nephrologists and patient associations.

Original languageEnglish
Pages (from-to)1249-1258
Number of pages10
JournalExpert Opinion on Drug Safety
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Human Influenza
Chronic Kidney Failure
Vaccination
Influenza Vaccines
Safety
Inactivated Vaccines
Expert Testimony
Immunosuppression
Healthy Volunteers
Infection

Keywords

  • End-stage renal disease
  • Influenza
  • Influenza prevention
  • Influenza vaccination
  • Influenza vaccine
  • Vaccine safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Influenza vaccination in patients with end-stage renal disease. / Principi, Nicola; Esposito, Susanna.

In: Expert Opinion on Drug Safety, Vol. 14, No. 8, 01.08.2015, p. 1249-1258.

Research output: Contribution to journalArticle

Principi, Nicola ; Esposito, Susanna. / Influenza vaccination in patients with end-stage renal disease. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 8. pp. 1249-1258.
@article{3e5179022efb48d39c26b4bdeb0843e5,
title = "Influenza vaccination in patients with end-stage renal disease",
abstract = "Introduction: Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than desired.Areas covered: This paper explores why compliance with official recommendations for influenza vaccination is poor in patients with ESRD and analyzes the true risk of infection as well as the immunogenicity, the effectiveness and the safety of influenza vaccination in these patients.Expert opinion: Epidemiological and clinical data support the importance of influenza in conditioning clinical deterioration of patients with ESRD, particularly in relation to their level of immunosuppression. However, the variable levels of immunodeficiency detected in patients with ESRD may reduce the immune response to influenza vaccination, which appears to be lower than that usually found in healthy subjects. However, few studies are available, and they are difficult to compare for several reasons. Additionally, limited data have been collected on influenza vaccine effectiveness, although the available studies support positive results of vaccination on outcomes of severe disease. Despite such limitations, it is important to highlight that all the available studies have confirmed the good safety and tolerability of inactivated influenza vaccines. These findings, together with the risks associated with influenza in these patients, support annual influenza vaccination in patients with ESRD as well as vaccination of their close contacts and should be presented in educational programs organized for nephrologists and patient associations.",
keywords = "End-stage renal disease, Influenza, Influenza prevention, Influenza vaccination, Influenza vaccine, Vaccine safety",
author = "Nicola Principi and Susanna Esposito",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/14740338.2015.1053459",
language = "English",
volume = "14",
pages = "1249--1258",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Influenza vaccination in patients with end-stage renal disease

AU - Principi, Nicola

AU - Esposito, Susanna

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction: Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than desired.Areas covered: This paper explores why compliance with official recommendations for influenza vaccination is poor in patients with ESRD and analyzes the true risk of infection as well as the immunogenicity, the effectiveness and the safety of influenza vaccination in these patients.Expert opinion: Epidemiological and clinical data support the importance of influenza in conditioning clinical deterioration of patients with ESRD, particularly in relation to their level of immunosuppression. However, the variable levels of immunodeficiency detected in patients with ESRD may reduce the immune response to influenza vaccination, which appears to be lower than that usually found in healthy subjects. However, few studies are available, and they are difficult to compare for several reasons. Additionally, limited data have been collected on influenza vaccine effectiveness, although the available studies support positive results of vaccination on outcomes of severe disease. Despite such limitations, it is important to highlight that all the available studies have confirmed the good safety and tolerability of inactivated influenza vaccines. These findings, together with the risks associated with influenza in these patients, support annual influenza vaccination in patients with ESRD as well as vaccination of their close contacts and should be presented in educational programs organized for nephrologists and patient associations.

AB - Introduction: Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than desired.Areas covered: This paper explores why compliance with official recommendations for influenza vaccination is poor in patients with ESRD and analyzes the true risk of infection as well as the immunogenicity, the effectiveness and the safety of influenza vaccination in these patients.Expert opinion: Epidemiological and clinical data support the importance of influenza in conditioning clinical deterioration of patients with ESRD, particularly in relation to their level of immunosuppression. However, the variable levels of immunodeficiency detected in patients with ESRD may reduce the immune response to influenza vaccination, which appears to be lower than that usually found in healthy subjects. However, few studies are available, and they are difficult to compare for several reasons. Additionally, limited data have been collected on influenza vaccine effectiveness, although the available studies support positive results of vaccination on outcomes of severe disease. Despite such limitations, it is important to highlight that all the available studies have confirmed the good safety and tolerability of inactivated influenza vaccines. These findings, together with the risks associated with influenza in these patients, support annual influenza vaccination in patients with ESRD as well as vaccination of their close contacts and should be presented in educational programs organized for nephrologists and patient associations.

KW - End-stage renal disease

KW - Influenza

KW - Influenza prevention

KW - Influenza vaccination

KW - Influenza vaccine

KW - Vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=84937250307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937250307&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1053459

DO - 10.1517/14740338.2015.1053459

M3 - Article

C2 - 26043970

AN - SCOPUS:84937250307

VL - 14

SP - 1249

EP - 1258

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 8

ER -